{"id":"0c11c4b255b8","type":"article","url":"https://hartvaat.nl/2016/04/21/mtp-131-bij-reperfusieschade-na-stemi-de-embrace-stemi-fase-2a-trial/","title":"MTP-131 bij reperfusieschade na STEMI: de EMBRACE STEMI fase-2a-trial","title_en":"EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehv597","source_url":"https://doi.org/10.1093/eurheartj/ehv597","authors":["C Michael Gibson","Robert P Giugliano","Robert A Kloner","Christoph Bode","Michal Tendera","András Jánosi","Bela Merkely","Jacek Godlewski","Rim Halaby","Serge Korjian","Yazan Daaboul","Anjan K Chakrabarti","Kathryn Spielman","Brandon J Neal","W Douglas Weaver"],"significance":5,"published":"2016-04-21","source_date":"2016-04-21","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"The EMBRACE STEMI phase 2a trial tested MTP-131 (elamipretide), a mitochondria-targeted peptide, for limiting reperfusion injury after STEMI, exploring subcellular cardioprotection during primary PCI.","created":"2026-07-03T10:26:03Z","updated":"2026-07-03T13:25:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Fase 2a-trial van intraveneus MTP-131, een mitochondriaal gericht peptide, voor beperking van reperfusieschade bij STEMI. Onderzocht een nieuw mechanisme voor myocardprotectie tijdens primaire PCI.","abstract_original":"AIMS: Among patients with ST-elevation myocardial infarction (STEMI), reperfusion injury contributes to additional myocardial damage. MTP-131 is a cell-permeable peptide that preserves the integrity of cardiolipin, enhances mitochondrial energetics, and improves myocyte survival during reperfusion. METHODS AND RESULTS: EMBRACE STEMI is a multicentre, randomized, double-blind Phase 2a trial that evaluated the efficacy and safety of MTP-131 vs. placebo infused at a rate of 0.05 mg/kg/h for 1 h among first-time anterior STEMI subjects undergoing primary percutaneous coronary intervention (PCI) for a proximal or mid left anterior descending (LAD) artery occlusion. Administration of MTP-131 was not associated with a significant reduction in the primary endpoint, infarct size by creatine kinase-myocardial band (CK-MB) area under the curve (AUC) over 72 h (5785 ± 426 ng h/mL in placebo vs. 5570 ± 486 ng h/mL in MTP-131; ITALIC! P = NS). MTP-131 was not associated with an improvement in pre-specified magnetic resonance imaging, angiographic, electrocardiographic, or clinical outcomes. CONCLUSION: Among subjects with first-time anterior STEMI due to a proximal or mid LAD lesion who undergo successful PCI, administration of MTP-131 was safe and well tolerated. Treatment with MTP-131 was not associated with a decrease in myocardial infarct size as assessed by AUC0-72 of CK-MB."}